Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

Clyde & Co | Insurance & Reinsurance UK

Emerging Risk | Semaglutides: weighing up the risks

22 Apr 2025

Description

The first episode of our 2025 podcast series covers Semaglutides, a diabetes control drug that works by activating glucagon-like peptide-1 (GLP-1) receptors to suppress appetite.

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.